
Balaji Amines Q2 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 1
Fundraise
N/A
Order
N/A
Capex
Yes
2 of 3 growth signals are positive.
Full analysisRevenue guidance
Category 3- The company expects growth and increased prospects in FY 2024-25 as market conditions improve.
- Ongoing projects (n-Butylamine, Methylamine, Dimethyl ether plants) are progressing on schedule, expected to add capacity.
- Volume improvement is anticipated post current destocking phase, with return to pre-COVID price levels within two quarters.
- Management is confident of margin improvement and better sales in the next two quarters.
- Targets to increase export contribution to 25%-30% in 1-2 years from current 15%-17% to hedge imports.
- Focus on new specialty products (NMM, NBPT, PVP K-30) first time in country, and solar power initiatives for sustainability.
- Current headwinds in pharma and agrochemical segments expected to ease after this quarter.
- Expect positive volume growth noted Y-o-Y despite recent revenue pressure due to realization impact.
See what Balaji Amines management said on margin guidance — free account, 30 seconds.
Fundraise plans
See what Balaji Amines management said on order book — free account, 30 seconds.
Capex plans
Yes- n-Butylamine plant expansion progressing rapidly; expected commission in Q4 FY 2023-24 (January-March 2024).
- Methylamine project on track; likely commission in Q2 FY 2024-25.
- Dimethyl ether (DME) plant initiated in Unit IV; civil works started; expected commission first half of FY 2024-25.
- Proposal for new products at Unit IV:
- - N-Methyl Morpholine (NMM) – 3,000 TPA
- - N-(n-butyl) Thiophosphoric triamide (NBPT) – 2,500 TPA
- - Pharmapure Povidone (PVP K-30) – 4,000 TPA (all first-time products in India)
- Solar power plant projects for captive consumption at Unit IV (~1,600 KW, costing approx INR 7.5 crores) aimed at ESG compliance and reducing carbon footprint.
- Initiated maintenance and debottlenecking in existing plants to improve product mix, realization, profitability, and capacity utilization.
- Proposal to acquire additional land for future expansions, including Balaji Specialty Chemicals Unit II with environmental clearance process underway.
Track Balaji Amines — get its next earnings analysis in your feed
How does Balaji Amines rank vs peers in Chemicals & Petrochemicals?
Pro featureHow does Balaji Amines rank in Chemicals & Petrochemicals?
Compare Balaji Amines against every Chemicals & Petrochemicals company (Q2 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Balaji Amines's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Seya Industries (Q2 FY27)
Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's
- DCM Shriram Fine Chemicals (Q2 FY27)
9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri
- Dhariwalcorp (Q2 FY27)
For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…
- Agastya Energy (Q2 FY27)
For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…